In addition to PD-1 and PD-L1 biomarkers, tumor mutational burden (TMB) is a promising biomarker to predict clinical outcomes of NSCLC patients to ICI immunotherapies (24–26), and was approved by the FDA in 2020. Here, PDCD1 is linked to neoplasm.